- Home
- RVMD vs IVZ Comparison
RVMD vs IVZ Comparison
Compare RVMD & IVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVMD
- IVZ
- Stock Information
- Founded
- RVMD 2014
- IVZ 1935
- Country
- RVMD United States
- IVZ United States
- Employees
- RVMD N/A
- IVZ N/A
- Industry
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- IVZ Investment Managers
- Sector
- RVMD Health Care
- IVZ Finance
- Exchange
- RVMD Nasdaq
- IVZ Nasdaq
- Market Cap
- RVMD 7.5B
- IVZ 7.0B
- IPO Year
- RVMD 2020
- IVZ 1995
- Fundamental
- Price
- RVMD $36.63
- IVZ $21.11
- Analyst Decision
- RVMD Strong Buy
- IVZ Hold
- Analyst Count
- RVMD 12
- IVZ 16
- Target Price
- RVMD $69.50
- IVZ $18.80
- AVG Volume (30 Days)
- RVMD 1.5M
- IVZ 8.9M
- Earning Date
- RVMD 08-06-2025
- IVZ 07-22-2025
- Dividend Yield
- RVMD N/A
- IVZ 3.96%
- EPS Growth
- RVMD N/A
- IVZ N/A
- EPS
- RVMD N/A
- IVZ 0.93
- Revenue
- RVMD N/A
- IVZ $6,153,100,000.00
- Revenue This Year
- RVMD N/A
- IVZ N/A
- Revenue Next Year
- RVMD $234.26
- IVZ $9.85
- P/E Ratio
- RVMD N/A
- IVZ $22.84
- Revenue Growth
- RVMD N/A
- IVZ 5.83
- 52 Week Low
- RVMD $29.17
- IVZ $11.60
- 52 Week High
- RVMD $62.40
- IVZ $21.85
- Technical
- Relative Strength Index (RSI)
- RVMD 51.68
- IVZ 70.47
- Support Level
- RVMD $36.20
- IVZ $20.08
- Resistance Level
- RVMD $38.60
- IVZ $21.85
- Average True Range (ATR)
- RVMD 1.25
- IVZ 0.72
- MACD
- RVMD 0.09
- IVZ -0.10
- Stochastic Oscillator
- RVMD 56.43
- IVZ 82.00
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).